How did Metz Property's operating profit change in Q1 2025?

Cannara Biotech's operating profit decreased in Q1 2025 compared to the previous quarter, while J & J Snack Foods' remained stable, with NeuroOne Medical Technologies' showing significant growth. MarineMax's showed a slight increase in gross profit margin but a decrease in net income. Jewett-Cameron Trading Company Ltd reported no change in operating profit for Q1 2025. 1. **Cannara Biotech**: The operating income for Cannara Biotech in Q1 2025 was $4.2 million, which is a decrease from the $5.1 million in Q4 2024. This decline is attributed to a lower unrealized fair value gain. 2. **J & J Snack Foods**: J & J Snack Foods reported an operating income of $6.2 million in the first quarter of fiscal 2025, compared to $9.7 million in the prior year period. This decrease in operating income contributed to a lower net earnings of $5.1 million in Q1 ’25 compared to $7.3 million in the same period of the previous year. 3. **NeuroOne Medical Technologies**: NeuroOne Medical Technologies reported a significant increase in product revenue, which was $3.3 million in the first quarter of fiscal 2025, a 235% increase from the $1.0 million in the same quarter of the previous year. This led to a product gross margin of 58.9% in Q1 2025, up from 27.2% in the same quarter of the previous year. The company also saw a decrease in operating expenses, which dropped by 12% to $3.2 million. 4. **MarineMax**: MarineMax's gross margin improved by 290 basis points year-over-year to 36.2% in Q1 2025, offsetting revenue decline and resulting in nearly flat Adjusted EBITDA. However, the net income of $18.1 million was achieved despite a 11% decrease in same-store sales and a hurricane impact on revenue. 5. **Jewett-Cameron Trading Company Ltd**: Jewett-Cameron reported no change in operating profit for Q1 2025, with the property being marketed for sale.